Molecular mechanisms and targeted interventions for embolic risk in cardiac myxoma: from molecular heterogeneity to clinical translation

Category	Detail
Condition	Cardiac Myxoma
Key Mechanisms	Tumor cell heterogeneity and an immunosuppressive microenvironment drive embolic risk.
Target Population	Patients with cardiac myxoma, particularly those at risk for embolic events.
Care Setting	Clinical oncology and cardiology

Cardiac myxoma is the most common primary cardiac tumor, with embolic events occurring in 10%-25% of patients.
Recent advances in single-cell and spatial transcriptomics have revealed the molecular basis of embolism in cardiac myxoma.
A specific PLAT-high tumor subpopulation and dysregulated phosphodiesterase signaling contribute to embolic risk.
M2 macrophages in the tumor microenvironment promote tumor survival and increase embolic potential.
Integration of molecular insights with clinical models is essential for personalized risk prediction.

Utilize clinical scoring systems that include age, smoking, atrial fibrillation, and tumor morphology.

Consider targeted therapies such as phosphodiesterase inhibitors and macrophage repolarization strategies.

Patients diagnosed with cardiac myxoma, especially those with high embolic risk.

Targeted interventions may reduce embolic risk preoperatively and postoperatively.

Integrate molecular profiling with traditional clinical assessments for risk stratification.
Monitor the tumor microenvironment for changes in macrophage polarization and tumor cell characteristics.

Clinical Scorecard: Molecular Insights and Targeted Strategies for Reducing Embolic Risk in Cardiac Myxoma: Bridging Molecular Diversity and Clinical Application